Tysabri (tie-SAB-ree), the latest investigational treatment for multiple sclerosis (MS)

There's a lot of excitement about Tysabri (tie-SAB-ree), the latest investigational treatment for multiple sclerosis (MS).

Tysabri (natalizumab) is a monoclonal antibody. It blocks immune cells from entering the CNS and attacking nerves.

It seems to be more effective than the other MS drugs.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote